June 2026: The Reclassification Happened — Then FDA's Own Scientists Said Not So Fast

Where Things Actually Stand

Three months ago we told readers to stop celebrating a podcast announcement and wait for the Federal Register. That was the right call — and the picture that has emerged since is more complicated than either the “peptides are legal again” crowd or the “nothing has changed” skeptics predicted.

Here is the honest summary as of the end of June 2026:

The reclassification is real. On April 15, 2026 the FDA republished its interim 503A bulk drug substances lists and announced the removal of 12 peptides from Category 2 — the “do not compound” list. The change took effect roughly a week later.
But “off Category 2” is not “legal to compound.” Removal from the prohibited list does not add these peptides to the 503A Bulk Drug Substances List. That requires a separate process: advisory-committee review, an FDA determination, and notice-and-comment rulemaking. Compounding these peptides remains outside the rules until that process completes.
The advisory committee meets July 23–24. And in the last week of June, two things happened that should give anyone paying attention pause: the FDA seated a new advisory panel packed with people who profit from peptides, while the agency’s own staff scientists published briefing documents concluding the evidence weighs against approval.

Let’s take these in order.

What the April Reclassification Actually Did

The event the whole market spent the spring waiting for finally arrived — quietly, and not quite in the form the announcement promised.

On April 15, 2026, the FDA republished its interim lists of bulk drug substances for use in 503A compounding. The agency announced its intent to remove twelve peptide bulk drug substances from Category 2. The removals were largely procedural: in most cases, the parties who had originally nominated these substances withdrew their nominations, and the FDA moved them off the significant-safety-concern list accordingly.

The twelve peptides removed from Category 2:

Peptide	Common association
BPC-157	”Healing” / regenerative
TB-500 (Thymosin Beta-4 fragment)	Recovery, tendon repair
KPV	Anti-inflammatory (α-MSH fragment)
MOTS-c	Mitochondrial / metabolic
Emideltide (DSIP)	Sleep
Semax	Cognitive (Russian-developed)
Epitalon	”Longevity” / telomere claims
Cathelicidin (LL-37)	Antimicrobial
GHK-Cu (injectable routes)	Cosmetic / skin
Melanotan II	Tanning / libido
PEG-MGF	Muscle growth
Dihexa acetate	Cognitive

The count nobody wants to correct

Recall that on the February 27 Joe Rogan appearance, HHS Secretary Robert F. Kennedy Jr. said he wanted roughly 14 of 19 Category 2 peptides moved back to Category 1. The actual April action moved 12 — and it moved them off Category 2, which is not the same as moving them onto Category 1.

This distinction is not pedantic. These peptides were never in Category 1 to begin with. Removal from the “do not compound” list drops them into a regulatory in-between: no longer prohibited, but not yet affirmatively permitted for compounding either. Every clinic website that told you “14 peptides are back in Category 1 and legal again” got two facts wrong in a single sentence.

The two-track structure

Of the twelve, the FDA split the review into two waves:

Seven peptides go before the Pharmacy Compounding Advisory Committee (PCAC) on July 23–24, 2026 (docket FDA-2025-N-6895): BPC-157, KPV, TB-500, and MOTS-c on July 23; Emideltide/DSIP, Semax, and Epitalon on July 24.
The remaining five — Cathelicidin/LL-37, GHK-Cu (injectable), Melanotan II, PEG-MGF, and Dihexa acetate — are slated for a later PCAC meeting expected before the end of February 2027.

Even a favorable PCAC vote is only advisory. The committee recommends; the FDA decides; and any addition to the 503A Bulk Drug Substances List then has to go through formal rulemaking. Specialist regulatory attorneys following this closely have noted that final rulemaking is realistically more than a year away — meaning the peptides under review in July could remain in compounding limbo well into 2027 or beyond, regardless of how the vote goes.

The Panel Problem

Here is where June got genuinely troubling for anyone who cares about the integrity of the process.

In the last week of June, reporting from STAT, the Associated Press (carried by PBS NewsHour and others), NPR, and NBC News documented that the FDA had seated a new slate of PCAC members for the peptide review — and that several of them have direct financial stakes in the peptides they are being asked to evaluate.

Among the named additions:

A physician who operates a chain of men’s-health clinics that market peptide therapy.
A physician with a public online presence promoting BPC-157 and GHK-Cu.
A pharmacist who also serves as a state legislator and is the son of a member of Congress who publicly lobbied the HHS Secretary to loosen peptide restrictions.

We want to be careful and fair here: having industry experience is not automatically disqualifying, and advisory committees routinely include practitioners. But an advisory committee evaluating whether a class of products should become legally compoundable should not be dominated by people whose businesses stand to benefit directly from a “yes” vote. That is not independent scientific review. It is the fox being invited to grade the henhouse’s security audit.

This is the exact dynamic PeptideExaminer exists to flag. When the people evaluating the evidence have a financial interest in a particular conclusion, the conclusion deserves extra scrutiny — not less.

FDA’s Own Scientists Disagree With the Hype

The counterweight arrived at the end of June from an unlikely source: the FDA itself.

Ahead of the July meeting, the FDA posted the scientific briefing documents its staff prepared for each of the seven peptides. As reported by NPR and U.S. News & World Report at the end of June and start of July, the agency’s reviewers were blunt:

On BPC-157: the human evidence amounts to essentially one small, poorly documented trial. There is no human data supporting the delivery routes being proposed for compounding. Reviewers flagged concerns about impurities, sterility, and immunogenicity.
On TB-500: the reviewers found zero human studies and no convincing nonclinical evidence of the healing effects the peptide is marketed for.

In other words: the FDA’s own scientists, reviewing the same evidence base we’ve been documenting in our peptide profiles for months, reached the same conclusion we did. The data is thin. For BPC-157 — the single most-hyped peptide on the market — it is close to nonexistent in humans.

Whether the industry-heavy advisory panel will weigh that staff analysis honestly is the question the July meeting will answer. We’ll be covering it in real time.

Enforcement Didn’t Pause for the Reclassification

A common misreading of the spring’s events is that the reclassification signaled a general regulatory retreat. The enforcement record says otherwise.

A wave of “research use only” warning letters landed at the end of March, posted publicly in early April. At least five peptide-sales websites received letters dated March 31, 2026 for selling unapproved new drugs — GLP-1 and related analogs (semaglutide, tirzepatide, retatrutide, and newer compounds like cagrilintide and mazdutide) — while hiding behind “research use only / not for human consumption” disclaimers. The confirmed recipients include Pink Pony Peptides (Lovega LLC), Mile High Compounds, PekCura Labs, Prime Sciences, and Gram Peptides. The FDA’s position, as it has been consistently: a “research only” label is negated by marketing copy that clearly targets human buyers.

In June, the FDA sent roughly 25 more warning letters to telehealth companies over compounded GLP-1 marketing — issued around June 8 and posted around June 16. The core allegation was that the “net impression” of the companies’ advertising falsely equated their compounded products with FDA-approved drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.

On the criminal side, the case against Matthew Kawa — connected to Paradigm Peptides and Amino Asylum — is heading toward sentencing. Kawa and a co-defendant pleaded guilty in the Northern District of Indiana; products sold as SARMs were found to actually contain testosterone, alongside unapproved peptides. Kawa’s sentencing has been scheduled for July 30, 2026. Separately, an April indictment in Utah charged a physician with importing misbranded peptides from China and reselling them to more than 200 patients.

The pattern is unchanged from what we described in the spring: the legal pathway is opening slowly and conditionally, while the illegal pathway keeps getting more dangerous to operate.

Market Intelligence Update

Metric	Data Point	Source
Peptides removed from Category 2 (April 15, 2026)	12	FDA interim 503A list / regulatory counsel
Peptides RFK Jr. said he wanted moved (Feb 27)	~14 of 19	Joe Rogan Experience
Peptides before PCAC on July 23–24	7	Federal Register, docket FDA-2025-N-6895
Peptides deferred to ~Feb 2027 meeting	5	Regulatory counsel
BPC-157 completed human RCTs supporting proposed routes	0	FDA staff briefing document
TB-500 human studies found by FDA reviewers	0	FDA staff briefing document
”Research use only” peptide-site warning letters (dated Mar 31)	5+ confirmed	FDA.gov warning-letter database
Telehealth GLP-1 warning letters (June)	~25	FDA / regulatory press
Estimated time to final 503A rulemaking	1+ year	Regulatory counsel analysis

What You Should Do Right Now

If you’re waiting to get these peptides through a compounding pharmacy legally: you’re not there yet. Removal from Category 2 did not make BPC-157 or TB-500 compoundable. Watch the July 23–24 PCAC meeting, but understand that even a favorable vote starts a rulemaking clock that runs a year or more. Anyone telling you these are “legal to compound now” is either misinformed or selling something.

If you’re evaluating the July meeting coverage: read it with the panel composition in mind. When you see a headline like “advisory panel recommends peptide access,” ask who was on the panel and what they sell. We’ll publish that breakdown.

If you’re currently buying grey-market: the enforcement trajectory has not softened. The March 31 letters, the June telehealth wave, and the Kawa sentencing all point the same direction they did last quarter.

If you’re weighing the science: note that the FDA’s own reviewers reached the same conclusion we have — the human evidence for the headline peptides is thin to nonexistent. Legal status, when it eventually changes, will not change what the studies do or don’t show. Start with our BPC-157 and TB-500 profiles for the actual evidence base.

PeptideExaminer — We don’t sell peptides. We tell you the truth about them.